NVL-655 is a medication being studied for its potential to treat patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. It works by selectively inhibiting a protein called anaplastic lymphoma kinase (ALK), which can be involved in the growth of cancer cells. The trial aims to assess the safety and tolerability of NVL-655, as well as its effectiveness in treating tumors that are positive for ALK, including those that have developed resistance to other treatments.

Advanced Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that is more common and generally grows and spreads more slowly than small cell lung cancer. It begins in the tissues of the lungs and can spread to other parts of the body. The disease is characterized by the presence of abnormal cells that form tumors in the lung tissue. As it progresses, it can cause symptoms such as persistent cough, chest pain, and difficulty breathing. The disease may also lead to weight loss and fatigue as it advances. It is often associated with genetic mutations, such as ALK rearrangement, which can influence its behavior and progression.

Solid Tumors with ALK Rearrangement or Activating ALK Mutation – These are a group of cancers that occur in various organs and are characterized by the presence of a specific genetic alteration known as ALK rearrangement or mutation. This genetic change can lead to uncontrolled cell growth and tumor formation. Solid tumors can develop in different parts of the body, including the lungs, brain, and other organs. The presence of ALK mutations can affect how the tumor grows and responds to certain treatments. Symptoms and progression can vary depending on the tumor’s location and size. These tumors are often studied for their unique genetic characteristics and potential targeted therapies.